Summit Therapeutics

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Employees: 105

Market Cap: $9.7B

Website

Introduction: Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company seeks to expand its product candidate portfolio through the development of new mechanism and precision antibiotics. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in Janua...

Clinical Trials

Phase III Study of AK112 for NSCLC Patients

Phase 3

Active, not recruiting

Conditions: Non-Squamous Non-small Cell Lung Cancer

Interventions: Drug: AK112 Injection
Drug: Placebo Injection

First Posted Date: 2024-05-02

Last Posted Date: 2024-10-08

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 420

Registration Number: NCT06396065

Locations: 🇺🇸
CBCC Global Research, Bakersfield, California, United States
🇺🇸
UC San Diego, La Jolla, California, United States
🇺🇸
University of Southern California, Los Angeles, California, United States

and more 70 locations

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Phase 3

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Ivonescimab Injection
Biological: Pembrolizumab Injection

First Posted Date: 2023-06-12

Last Posted Date: 2024-12-20

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 1080

Registration Number: NCT05899608

Locations: 🇨🇦
Summit Therapeutics Research Center, Regina, Saskatchewan, Canada
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

Phase 3

Terminated

Conditions: Clostridioides Difficile Infection

Interventions: Drug: Ridinilazole
Drug: Vancomycin

First Posted Date: 2021-03-17

Last Posted Date: 2023-08-21

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 2

Registration Number: NCT04802837

Locations: 🇺🇸
Stony Brook University Medical Center, Stony Brook, New York, United States
🇺🇸
Continental Clinical Research, Miami, Florida, United States
🇺🇸
Indiana University Health - Riley Hospital for Children, Indianapolis, Indiana, United States

and more 15 locations

Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection

Phase 3

Completed

Conditions: Clostridioides Difficile Infection

Interventions: Drug: Vancomycin
Drug: Ridinilazole

First Posted Date: 2018-07-23

Last Posted Date: 2023-03-03

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 759

Registration Number: NCT03595553

Locations: 🇧🇬
DCC1-Sliven Ltd., Sliven, Bulgaria
🇬🇷
''Tzaneio'' General Hospital of Piraeus, Piraeus, Greece
🇭🇺
Dr. Kenessey Albert Kórház Rendelőintézet, Tüdőgyógyászati Aktív Osztály, Balassagyarmat, Hungary

and more 146 locations

Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)

Phase 2

Terminated

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: Ezutromid

First Posted Date: 2016-08-08

Last Posted Date: 2020-01-02

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 43

Registration Number: NCT02858362

Locations: 🇺🇸
Nemours Children's Clinic, Orlando, Florida, United States
🇬🇧
Bristol Children's Hospital, Bristol, United Kingdom
🇬🇧
Heart of England NHS Foundation Trust - Heartlands Hospital, Birmingham, United Kingdom

and more 13 locations

A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)

Phase 2

Completed

Conditions: Clostridium Difficile Infection

Interventions: Drug: Fidaxomicin
Drug: Ridinilazole

First Posted Date: 2016-05-26

Last Posted Date: 2017-10-12

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 27

Registration Number: NCT02784002

Locations: 🇺🇸
Laguna Hills, Laguna Hills, California, United States
🇺🇸
Ventura, Ventura, California, United States
🇨🇿
Pardubice, Pardubice, Czechia

and more 13 locations

Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet

Phase 1

Completed

Conditions: Muscular Dystrophy, Duchenne

Interventions: Drug: SMT C1100

First Posted Date: 2015-03-09

Last Posted Date: 2015-08-26

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 12

Registration Number: NCT02383511

Locations: 🇬🇧
Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
🇬🇧
Heart of England NHS Foundation Trust - Heart Lands Hospital, Birmingham, United Kingdom
🇬🇧
Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom

and more 1 locations

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

Phase 2

Completed

Conditions: Clostridium Difficile Infection

Interventions: Drug: SMT19969
Drug: Vancomycin

First Posted Date: 2014-03-20

Last Posted Date: 2016-10-20

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 100

Registration Number: NCT02092935

A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)

Phase 1

Completed

Conditions: Duchenne Muscular Dystrophy

Interventions: Drug: SMT C1100

First Posted Date: 2014-02-06

Last Posted Date: 2014-08-27

Lead Sponsor: Summit Therapeutics

Target Recruit Count: 12

Registration Number: NCT02056808

Locations: 🇬🇧
Heart of England NHS Foundation Trust - Heart Lands Hospital, Birmingham, United Kingdom
🇬🇧
Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom
🇬🇧
Great Ormond Street for Children NHS Foundation Trust, London, United Kingdom

and more 1 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy